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The growth hormone-releasing hexapeptide (GHRP-6) 
specifically stimulates growth hormonc (GH) secretion in 
several animal species and humans. The mechanism of 
action of GHRP-6 is largely unknown, although experimen- 
tal evidence indicates that i t  may modulate growth hor- 
mone-releasing hormone (GHRH) and somatostatin ac- 
tions at the pituitary or hypothalamic level. To  gain more 
insight into the mechanism(s) of action of GHRP-6, we 
studied the infant rat, an animal model highly responsive to 
GH-releasing stimuli. In 14-d-old rats GHRP-6 (32-600 
pgikg, LC.) induced a marked and dose-dependent rise in 
plasma GH concentrations, maximal stimulation occurring 
with the dose of 300 pgikg. Neither GHRH nor somato- 
statin antiserum prevented or modified the G H  release 
elicited by GHRP-6. In pups passively immunized with 
GHRH antibodies, a 5-d treatment with GHRP-6 (80 pgikg, 
s.c., twice daily) completely counteracted the inhibitory 
effect of GHRH deprivation on G H  mRNA expression. It1 
GHRP-6 is a synthetic peptide that specifically stimu- 
lates growth hormone release in all species so far inves- 
tigated (1-3). Although GHRP-6 has been shown to stim- 
ulate GH release irz virro from rat primary pituitary cell 
cultures (4, 5), it shows a far greater GH-releasing activ- 
ity when administered in viva (6-8). These observations 
suggest that GHRP-6 stimulates GH secretion by acting 
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iitro GHRP-6 ( I W 7  and 10  " M) induced a small and 
transient stimulation of G H  release from cultured pituitary 
cells. These results indicate the following: I )  GHRP-6 is a 
potent stimulator of G H  release in rat pups; 2) it stimulates 
G H  gene expression in the GHRH-deprived pup; .?) during 
the neonatal period its action is not mediated by GHRH or 
somatostatin; and 4) its actions are not directed at the 
somatotrophs. (Pediatr Res 36: 169-174, 1994) 
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on two sites, the pituitary and the hypothalamus. In 
keeping with these findings, receptor binding sites for 
GHRP-6 have been demonstrated in both tissues (9). 
Experimental evidence has indicated that GHRP-6 does 
not bind to the GHRH receptor (7) or activate adenylate 
cyclase (4). However, in vivo studies have shown that 
GHRP-6 potentiates the GH-releasing effect of GHRH 
when the peptides are coadministered into humans (8) or 
adult rats (lo),  and passive immunization against GHRH 
attenuates the GH response to GHRP-6 (11). Overall, it 
appears that in vitro results imply independent mecha- 
nisms for GHRP-6 and GHRH at the level of the pituitary 
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To gain more insight into the mechanism(s) underlying 
the GH-releasing activity of GHRP-6, we used the infant 
rat, an animal model well suited for evaluating GH- 
releasing stimuli (12-14). First, we evaluated the GH- 
releasing effect of increasing doses of GHRP-6 in vivo. 
We then tested the GH-releasing effect of GHRP-6 in 
vitro and compared it to that occurring after GHRH. We 
then studied the involvement of GHRH and somatostatin 
in the mechanism of action of GHRP-6 by the use of 
passive immunization with specific antisera against 
GHRH and somatostatin. Finally, we evaluated the ca- 
pacity of GHRP-6 to affect pituitary GH gene expression 
in rats deprived since birth of endogenous GHRH. 
METHODS 
Animals 
Male and female 10- and 14-d-old Sprague-Dawley rats 
(Charles River Breeding Laboratories, Calco, Italy) 
weighing approximately 25 and 35 g, respectively, were 
used. They were received on the day of birth and were 
housed under controlled conditions (22 2 2"C, 65% hu- 
midity and artificial light from 0600-2000 h). A standard 
dry diet and water were available ad libitum to the dams. 
One hour before the experiments, pups were separated 
from their respective dam and were randomly divided 
into groups of eight. All the experiments were performed 
in accordance with the Italian Guidelines for the Use of 
Animals in Medical Research. 
Antiserum to GHRH and Somatostatin 
The GHRH-ab, prepared and validated by one of us 
(W.B.W.), has been repeatedly found to inhibit normal 
GH secretion and slow growth (15-18). In a previous 
study (16) we evaluated the effect of GHRH-ab (50-200 
pL/rat) injected into 10-d-old rats on GH secretion. On 
the basis of that study, a dose of 100 pL/rat was chosen 
because it maximally inhibited GH secretion. The so- 
matostatin-ab was prepared by immunizing rabbits with 
synthetic somatostatin conjugated to BSA and glutaral- 
dehyde. The antiserum is directed toward the middle part 
of somatostatin and does not cross-react with other hy- 
pothalamic, pituitary, and gastrointestinal peptide hor- 
mones. One hundred FL of the undiluted antiserum were 
able to neutralize approximately 600 ng of somatostatin, 
an amount that greatly exceeds that present in the 14-d- 
old rat. 
Experimental Procedure 
In vivo experiments. In the first series of experiments 
pups received a single S.C. injection of different doses of 
GHRP-6 (Bachem, Bubendorf, Switzerland) (i.e. 0, 16, 
32, 150, 300, and 600 &kg dissolved in physiologic 
saline). Animals were killed by decapitation 20 min later. 
In the second experiment, pups received a S.C. injec- 
tion of 100 p L  of a GHRH-ab (15) or somatostatin-ab (13) 
or 100 p L  of both antiserum (GHRH-ab + somatostatin- 
ab), or 100 p L  NRS. One h later they received a S.C. 
injection of GHRP-6 (300 p.g/kg) and were killed by 
decapitation 20 min after GHRP-6 injection. Trunk blood 
was collected and immediately centrifuged. Serum sam- 
ples were stored at -20°C until assayed for GH. 
In the third experiment aimed at evaluating the ability 
of GHRP-6 to stimulate GH synthesis, pups were given 
GHRH-ab (100 pLlrat) on d 1, 2, 4, 6, 8, and 10 of age. 
Control-treated rats received an equal volume of NRS. 
Beginning on d 6 or 8 and up to d 10, pups were given 
GHRP-6 (80 pg/kg, s.c., twice daily) or physiologic sa- 
line. Twelve h after the last administration of GHRP-6, 
pups were killed, and the pituitary gland was quickly 
dissected and frozen on dry ice for the determination of 
GH gene expression. 
In vitro experiments. Pups were killed by decapitation, 
and the pituitary glands were rapidly dissected. Pituitary 
tissue used for cell dissociation included both the anterior 
and posterior lobes. Briefly, pituitary glands were col- 
lected in sterile F-10 medium (Sigma Chemical Co., St. 
Louis, MO). Tissue was cut into small fragments and 
incubated twice for 15 min at 37°C in F-10 medium 
containing 6% FCS and collagenase (2.5 mg/mL) (Boeh- 
ringer, Mannheim GmBH, Germany). Fragments were 
then washed in Dulbecco's PBS, Ca2+- and  free 
medium (Sigma Chemical Co.), and mechanically disso- 
ciated. Single-cell suspensions were plated onto 24-well 
(2 x 10' cellslwell) culture plates. The cells were incu- 
bated in F-10 medium supplemented with 10% horse 
serum, 4% FCS, and gentamycin (25 kg/mL) in a humid- 
ified atmosphere of 5% CO, and 95% air at 3TC. After 3 
d, the medium was removed, and the cells were washed 
twice with serum-free F-10. The cells were then incu- 
bated in 1 mL of F-10 containing 0.1% BSA with no G H  
secretagogue or GHRP-6 (lo-", lo-', lo-' M) or GHRH 
(human GHRH-44, lo-' M; Bachem, Philadelphia, PA) 
or GHRP-6 lo-' M plus GHRH lo-' M. Media collected 
at the end of 15- and 30-min incubations were immedi- 
ately frozen and stored at -20°C until assayed for GH 
content. 
Pituitary GH Gene Expression 
Total RNA was isolated by a single-step, acid guanid- 
ium thiocyanate-phenol-chloroform extraction method 
(19). Total RNA samples (20 pg/sample) were run on a 
1.2% formaldehyde agarose gel and transferred to nylon 
membranes (Hybond N, Amersham, Little Chalfont, 
UK). The membranes were hybridized with a cDNA 
probe specific for rat GH (kindly provided by F. De 
Noto, University of California, San Francisco, CA). The 
cDNA probe was labeled by random primer (Megaprime, 
Amersham) with O ~ - " P C ~ C T P  to a specific activity of 1 x 
10' dpmlpg DNA. The nylon filters were rehybridized 
with a " ~ - " P ~ ~ c T P  labeled rat glyceraldehyde 3-phos- 
phate dehydrogenase (G3PDH) probe to control for ho- 
mogeneity of RNA loading. Autoradiography was carried 
out at -70°C for 16-24 h with intensifying screens. Quan- 
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tification of hybridization signal was performed on a 
scanning densitometer (LKB XL, Laser Densitometer, 
Uppsala, Sweden). Pituitary GH mRNA levels were ex- 
pressed as percentage of control group values. 
GH Assay 
GH concentrations in serum and in the pituitary culture 
media were measured by RIA with materials kindly pro- 
vided by the National Institute of Diabetes, Digestive and 
Kidney Diseases of the National Institutes of Health. 
Values are expressed in terms of National Institute of 
Diabetes and Digestive and Kidney Diseases-rat-GH- 
RP-2 standard (potency 2 IU/mg) as pg/L of plasma or 
medium. The minimum detectable value of rat GH was 
1.0 p a ;  intraassay variability was 6%. To avoid interas- 
say variations, we assayed samples from each experi- 
ment within one RIA. 
Statistical Analysis 
Statistical differences were evaluated by the Dunnett's 
r test for multiple comparisons, preceded by analysis of 
variance. A p  value less than 0.05 was considered signif- 
icant. 
RESULTS 
Preliminary experiments had indicated that in rat pups 
serum GH levels peaked 20 min after the s.c. injection of 
GHRP-6 (data not shown). Therefore, blood samples 
from all subsequent studies were collected at that time. 
Administration of GHRP-6 elicited a marked ( p  < 0.05) 
rise in plasma G H  concentrations at doses of 32, 150,300, 
and 600 pg/kg (272, 327, 456, and 411% increase over 
saline-treated rats, respectively). The dose of 16 pgkg 
did not stimulate GH secretion and that of 300 pg/kg 
resulted in a maximal response (Fig. 1). 
GHRP-6 and M) stimulated GH release from 
primary pituitary cell cultures at 15 min (increase over 
basal levels, 47 and 37% for GHRP-6 10-"nd M, 
respectively, p < 0.05); however, such stimulation was 
not observed at 30 min of incubation. At both time 
intervals, GHRP-6 M) failed to stimulate GH re- 
lease (Fig. 2). GHRH (lo-' M) alone or in combination 
with GHRP-6 (lo-' M) was effective in stimulating GH 
release at 15 (increase over basal levels, 43 and 52% for 
GHRH alone and GHRH + GHRP-6, respectively) and 
30 min (47 and 52% for GHRH and GHRH + GHRP-6, 
respectively) (Fig. 2). The action of the two peptides was 
neither additive nor synergistic. 
In vivo, 1 h after GHRH-ab administration, basal 
plasma GH levels were significantly reduced. No signif- 
icant effect was evident on basal GH levels after treat- 
ment with somatostatin-ab or the combination of the two 
antisera. G H  significantly increased in response to 
GHRP-6 (300 pgkg, s.c.), and this response was not 
altered by antiserum pretreatment (Fig. 3). 
GHRP-6 (pg/kg)  
Figure 1. A representative dose-response curve of GHRP-6 on plasma 
GH concentrations in 14-d-old male and female rats. GHRP-6 (16, 32, 
150, 300, and 600 & k g )  or physiologic saline were administered S.C. 20 
min before sample collection. Data are the mean ? SEM of nine 
replicates for each treatment group. Similar results were obtained in 
three similar independent experiments. *, p c 0.05 1,s vehicle. 
Passive immunization of GHRH from d 1 to d 10 of age 
significantly reduced pituitary GH mRNA expression 
(42% inhibition versus NRS + saline-treated pups; p < 
0.05) (Fig. 4). GHRP-6 replacement therapy from d 8-10 
of age resulted in only a slight increase in GH gene 
expression (21% increase versus GHRH-ab + saline- 
treated pups), but replacement therapy from d 6-10 re- 
sulted in full restoration of the GH mRNA expression to 
control levels (74% increase over GHRH-ab + saline- 
treated rats; p < 0.05). GHRP-6 treatment did not stim- 
ulate GH mRNA expression in the NRS-treated rats. 
DISCUSSION 
GHRP-6 elicited a marked, dose-related rise in plasma 
GH in infant rats. Its effects were apparently independent 
of endogenous GHRH and somatostatin release. Indeed, 
under our experimental conditions, functional blockade 
of the hypothalamic control of GH secretion by passive 
immunization with specific antisera against GHRH and 
somatostatin failed to alter GHRP-6-induced GH secre- 
tion. In infant rats after short-term GHRH deprivation, 
the hexapeptide was an effective stimulator of GH gene 
expression. However, in pituitary cultures GHRP-6 
poorly and transiently stimulated GH release. Thus, we 
conclude that in infant rats: 1) GHRP-6 is a potent stim- 
ulator of GH release; 2) its action occurs primarily at the 
hypothalamic level; 3) the mode of action of GHRP-6 is 
independent from the classic neuroendocrine control of 
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Figure 2. Effect of GHRP-6 and GHRH on G H  release from 14-d-old 
rat pituitary cells. Cells (200,000 cells/well) were incubated with 
GHRP-6 (lo-', lo-', and lo-' M), GHRH (lo-" M), GHRP-6 (lo-'  M) 
+ GHRH (lo-" M)  or  medium alone for 15 or  30 min. Values are the 
mean + S E M  of six replicates and are representative of the results 
ohtained in three similar independent experiments. *, p < 0.05 vs 
medium alone. 
the hypothalamus; and 4) GHRP-6 is a stimulator of GH 
gene expression in GHRH-deprived rats. 
Our data in the infant rat contrast those obtained in 
adult rats. Clark et al. (11) and Bercu et al. (10) have 
shown that in the adult rat passive immunization against 
GHRH produced partial or nearly complete suppression 
of GHRP-6 activity, indicating that in the adult rat GHRH 
is a prerequisite for full expression of GHRP-6 activity. 
In this vein, it has been shown that systemic GHRP-6 
administration activates subpopulations of GHRH neu- 
rons in the rat arcuate nucleus (20). However, several 
reports have been presented suggesting that GHRP-6 and 
GHRH operate by distinct receptors (4, 6, 21, 22). 
Inhibition of endogenous somatostatin activity has also 
been proposed as a mechanism of GHRP-6 action in the 
adult rat (11) and in humans (23). However, in our hands 
depletion of hypothalamic somatostatin stores by cyste- 
amine (24) did not impair the GH-releasing effect of 
GHRP-6 in adult rats (25). The reason for the discrepan- 
cies between these results and those of the present study 
may reside in the age of the animals studied. Infant rats, 
0 Saline GHRP-6 
T 
Figure 3. Effect of passive immunization with GHRH-ab and/or so- 
matostatin-ah on GHRP-6 stimulated of G H  secretion in 14-d-old rats. 
Groups of rats were injected with 100 p L  NRS, 100 p L o f  GHRH-ah or  
somatostatin-ah, or 100 p L  GHRH-ah + 100 p L  somatostatin-ah 1 h 
before administration of GHRP-6 (300 ~ g i k g ,  s.c.) o r  physiologic saline. 
Blood samples were obtained at 20 min after GHRP-6 administration. 
Values are the mean + SEM of six to eight replicates and are repre- 
sentative of the results obtained in three similar independent experi- 
ments. *, p < 0.05 rts NRS-treated rats. 
NRS GHRH-ab 
[ Saline GHRP-6. 3-days GHRP-6. 5-days 
Figure 4. Effect of GHRP-6 on G H  gene expression in 10-d-old rat 
pituitaries. Pups were given NRS or  GHRH-ah (100 pL/rat/d) on d 1, 2, 
4, 6, 8, and 10 of age. GHRP-6 (80 pgikg, s.c., twice daily) o r  physio- 
logic saline was administered from d 8 to 10 (3  d )  o r  from d 6 to 10 (5 d). 
Data obtained from two independent similar experiments were evalu- 
ated by densitometry, expressed a s  a percentage of the NRS + saline 
group and pooled. n = 2C24 rats for each data point. *, p < 0.05 vs 
NRS + saline; #, p < 0.05 vs GHRH-ab + saline. 
when compared with adult rats, are more sensitive to G H  
secretagogues (12, 13, 26-28) but less sensitive to the 
inhibitory control of somatostatin (29). 
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Proper interpretation of GHRP-6 mechanism of action 
is further compounded by recent data on GHRP-6 stim- 
ulation of GH secretion in rats with surgical ablation of 
the hypothalamus (25,30) and in hypophysectomized rats 
bearing ectopic pituitary grafts (30). It is possible that 
GHRP-6 stimulates GH secretion in vivo through several 
pathways. For example, stimulation may involve some 
uncharacterized hypothalamic factor, some specific pitu- 
itary receptor, or some unknown peripheral factor. The 
relative weight of such mechanism(s) in mediating 
GHRP-6 action in infants rats may be different than in 
adult rats. It has been shown that stimuli that are inef- 
receptor, present in the adult pituitary (Y), is not ex- 
pressed or is functionally immature. 
In conclusion, the present study indicates that in infant 
rats: 1) GHRP-6 is a potent stimulator of GH release; 2) 
it stimulates GH gene expression in the GHRH-deprived 
pup; 3) its action is not mediated by GHRH or somato- 
statin; and 4) its site of action is not on the somatotrophs. 
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